Gabapentin Capsule
Product Images NDC 68788-4107

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68788-4107). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin Capsules 100mg (100mg 500count)

Label for Gabapentin Capsules 100 mg by Preferred Pharmaceuticals Inc., featuring a capsule dosage form. The label includes storage instructions, manufacturer Hetero Labs Limited, directions for use in English and Spanish, and barcode information. It highlights the generic nature of the drug for Neurontin and notes standard prescription warnings.*

FDA Label Image

Equation (Equation)

A mathematical formula illustrating creatinine clearance (CLCr), used for estimating kidney function, involving patient age, weight, serum creatinine, and adjustment for female patients.*

FDA Label Image

Fig 1 (Fig 1)

A line graph titled 'Figure 1. Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 1' showing mean pain scores on the y-axis (scale 0-10) over 8 weeks on the x-axis. Two data series compare placebo and gabapentin 3600 mg/day, with gabapentin showing a gradual decrease in pain scores over time compared to placebo. Periods for 1-week dose titration and 4-week fixed dose are indicated.*

FDA Label Image

Fig 2 (Fig 2)

A line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 2' showing mean pain scores over a baseline and seven weeks. The graph compares placebo with gabapentin at doses of 1800 mg/day and 2400 mg/day, illustrating pain score trends during 4-week dose titration and 4-week fixed dose periods.*

FDA Label Image

Fig 3 (Fig 3)

A bar chart showing the proportion of responders (patients with at least 50% reduction in pain score) at endpoint in controlled postherpetic neuralgia (PHN) studies. The chart compares placebo (PBO) and gabapentin (GBP) at doses 1800 mg, 2400 mg, and 3600 mg, with response rates higher in gabapentin groups ranging from 29% to 34%, versus 12% and 14% in placebo groups across two studies.*

FDA Label Image

Fig 4 (Fig 4)

A scatter plot showing the responder rate difference (%) from placebo in patients taking gabapentin, stratified by daily dose (mg) and study group (Study a, Study b, Study c). The x-axis represents daily gabapentin dose from 600 to 1800 mg, and the y-axis shows difference percentages ranging from 2 to 22%. Data points for each study are plotted at different doses, illustrating variation in response rates.*

FDA Label Image

Structure (Struct)

Chemical structure diagram of the active ingredient gabapentin. The structure shows a cyclohexane ring with attached amine (CH2NH2) and carboxylic acid (CH2CO2H) functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.